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Tuberculosis (TB) is a major global public health problem causing significant mortality and
morbidity. In addition to ∼10.4 million cases of active TB annually, it is estimated that
about two billion people are latently infected with Mycobacterium tuberculosis (Mtb),
the causative agent of TB. Reactivation of latent Mtb infection is the leading cause of
death in patients with immunodeficiency virus (HIV) infection. The low efficiency of the
only licensed anti-TB vaccine, Bacille Calmette–Guérin (BCG) to reduce pulmonary TB in
adults contributes to this problem. Here we investigated if vaccination with conventional
BCG or the genetically modified experimental BCG1BCG1419c strain can prevent
reactivation of latent lymphatic TB in a mouse model of induced reactivation, following the
depletion of CD4+ T cells, as it occurs in HIV+ individuals. Vaccination with conventional
BCG or BCG1BCG1419c prevented reactivation of Mtb from the infected lymph node
and the systemic spread of Mtb to spleen and lung. Prevention of reactivation was
independent of vaccination route and was accompanied by reduced levels of circulating
inflammatory cytokines and the absence of lung pathology. Our results demonstrate that
vaccine-induced CD4+ T cells are not essential to prevent reactivation of latent lymphatic
murine TB, and highlight the need to better understand how non-CD4+ immune cell
populations participate in protective immune responses to control latent TB.
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INTRODUCTION
Tuberculosis (TB) affects ∼10.4 million people annually and is associated with 1.7 million
deaths per year (1). Despite the availability of effective anti-TB drugs, poor adherence to long
treatment regimens contributes to the emergence of multi drug-resistant strains ofMycobacterium
tuberculosis (Mtb), the causative agent of TB (1). Additionally, it is estimated that about 2 billion
people are latently infected withMtb without showing signs of active disease (1).
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The immune system usually contains Mtb infection through
the formation of granulomatous lesions (2). However,
immunosuppressed individuals such as those who have co-
morbid human immunodeficiency virus (HIV) infection or
diabetes mellitus have an impaired ability to control latent TB
infection (LTBI) (3), resulting in active disease and transmission.
In fact, reactivation of LTBI is the number one cause of death
in HIV co-infected individuals (4, 5). The gradual decline of
CD4+ T cells, the hallmark of HIV infection, is believed to be
a major contributing factor in LTBI reactivation (2). CD4+ T
cells are a major source of interferon gamma (IFN-γ), a critical
cytokine for TB control, and essential for the structural integrity
of the granulomas (6). However, the precise role CD4+ T cells
play in immunity to TB remains a matter of debate (7, 8).
In this context, it is interesting that although anti-retroviral
therapy largely restores CD4+ T cell numbers, the increased
risk for reactivation of LTBI is only partially diminished (9),
and reactivation of LTBI often occurs early after HIV infection
(10). Furthermore, in a macaque model of TB/SIV co-infection,
suppression of LTBI reactivation was shown to be independent
of CD4+ T cells in at least one third of animals (11). In addition,
it was very recently demonstrated that a higher monocyte and
macrophage turnover was responsible for LTBI reactivation in
macaques co-infected with Mtb and simian immunodeficiency
virus (SIV) (12). Collectively, these findings further challenge the
assumption that CD4+ T cells are irreplaceable in TB.
The only licensed TB vaccine, Bacille Calmette–Guérin
(BCG) is universally used. BCG efficiently prevents miliary
and meningeal TB in children, but shows low efficacy against
pulmonary TB in adults (13), and hence does not prevent the
transmission cycle (14). Over the last decades several new TB
vaccines have been developed with a few currently undergoing
clinical trials (15). The important role of IFN-γ-secreting CD4+
T cells in animal studies, has led to cognate activation and
expansion of Mtb-specific CD4+ T cells through the use of
immunodominant Mtb antigens being the main strategy for
many new TB vaccines under development (16). However,
the recent failures of the TB vaccine candidate MVA85A,
(17, 18) highlight the need to rethink TB vaccine design and
to identify CD4-independent mechanisms that contribute to
control of TB. Importantly, it has become increasingly clear
that the immunological correlates of vaccine induced protection
against Mtb are not fully understood and seem to differ
between experimental TB vaccines (7, 8). BCG is administered
intradermally in early childhood and most TB vaccine candidates
in clinical trials are also administered intradermally (19, 20).
However, a shortcoming of intradermal BCG administration is
the development of weak memory lymphocyte responses, which
lack mucosal homing chemokine receptors, such as CCR5 and
CXCR3, that allow migration to the lung, the initial site of Mtb
infection (21). To match the route of vaccination to the route of
natural infection, mucosal vaccination into the lung has attracted
renewed interest (9, 22–24). It is now clear that vaccination
directly into the respiratory tract (aerosol, i.n. and i.t.) generates
more protective lung-residing memory T cells (9, 22, 25).
Recombinant BCG strains and attenuated Mtb strains
have received significant attention as potential replacement
vaccines for BCG (13, 26). Live vaccines often elicit a broader
immune response compared to protein-based formulations
and do not require an adjuvant. The recombinant BCG
1ureC::hly (VPM1002), and the attenuatedMtb1phoP1fadD26
(MTBVAC) are currently undergoing testing in various clinical
trial stages (27, 28). Other experimental live recombinant
BCG vaccines, such as BCG1BCG1419c, BCG 1zmp1, and
BCG::ESX-1Mar, have shown promising results in animal models
but have not yet reached human trials (29–32). Similarly,
attenuated Mtb strains, such as Mtb 1sigH (33) and Mtb
1RD1 1panCD (34) showed increased protection, improved
safety and better antigen-specific immune responses in various
animal models. The live attenuated BCG-based vaccine candidate
BCG1BCG1419c was developed following the hypothesis that
chronic mycobacterial infections and LTBI reproduce aspects of
biofilm-formation, and contain different antigens compared to
planktonic bacteria (35, 36). BCG1BCG1419c showed improved
protection against chronic Mtb infection in BALB/c mice and
prevented reactivation from latent-like infection of B6D2F1 mice
(29), as well as improved protection against chronicMtb infection
of C57BL/6 mice, compared to parental BCG (37). Recently,
proteomic comparison of BCG1BCG1419c has shown that in
comparison to BCG, it slightly reduces its production of antigenic
proteins such as PstS2, HbhA, CFP17, DnaK, and 35 KDa antigen
(38) and transcriptomic comparison of the same strains showed
that BCG1BCG1419c had reduced expression of groEL1, kasA,
fas, fabD, acpM, and kasB, involved in mycolic acid biosynthesis,
as well as reduced transcription of genes hspX, groEL2, and
groES, which encode for antigenic chaperones (37), globally
contributing to a reduced inflammatory environment during
chronic infection.
Several meta-analyses of human studies have found that
BCG vaccination protects against active tuberculosis (39–45).
However, due to a lack of long-term human follow-up studies
and the lack of studies regarding LTBI reactivation in the animal
model thatmost closely resembles LTBI, the non-human primate,
in the context of vaccination solely with BCG, it is currently
unknown if BCG vaccination also impacts on the reactivation
dynamics of LTBI in the context of HIV. Recent mathematical
modeling data provided new evidence on the global prevalence of
LTBI (46), but fell short of estimating the role of BCG vaccination
on LTBI reactivation. A very recent study also found no difference
in the prevalence of LTBI in the UK, where the relative incidence
between BCG vaccinated and naïve people was compared (47).
Another very recent report predicted the possible estimation
of the role of BCG vaccination on reactivation from LTBI, but
the final outcome is yet to be reported (48). In a statistically
underpowered Taiwanese study the percentage of T-SPOT.TB
positive, HIV-infected patients, was almost 50% less in people
showing a BCG scar compared with those with no evidence of
BCG vaccination, therefore suggesting BCG reduces reactivation
from LTBI in a HIV setting (49). Hence, in order to better
understand the correlates of BCG-induced protection against
LTBI reactivation, better models and a deeper understanding of
the underlying immune response are required.
Non-human primate models forMtb/SIV co-infection closely
resemble human physiology, but are associated with substantial
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ethical, financial, and logistical limitations (50). We have
recently described a new tractable mouse model to study
reactivation of LTBI, following the loss of CD4+ T cells similar
to what occurs in HIV co-infection in humans (51). In this
model intradermally (i.d.) infected C57BL/6 mice contain Mtb
within the local draining lymph nodes (LN) until depletion
of CD4+ cells occurs, thereby mimicking the reactivation of
LTBI following HIV infection. In contrast, Mtb-infected CD4-
deficient mice andMHC-II deficient mice do not recapitulate the
latent aspect of LTBI but rather only show exacerbated disease
relative to C57BL/6 mice (52). It was recently proposed that
TB has characteristic features of lymphatic diseases and that
pulmonary pathology may primarily serve disease transmission
(53). The hypothesis that Mtb persistence may occur in the
lymphatics is supported by historical descriptions of TB cases,
experimental models and observations of TB in non-human
hosts (53). This model is also supported by recent findings that
Mtb persists in bone marrow stem cells (54–57). Additional
evidence for the importance of lymphatic persistence in LTBI
has recently also been provided in high-profile NHP studies
(11, 58). In this context, the robust mouse LTBI reactivation
model presents a much needed alternative to study LTBI
compared to logistically challenging NHP models, and provides
an opportunity to thoroughly investigate the importance of
CD4+ T cell-independent strategies for TB vaccination, which
are likely to significantly contribute to the immune response
elicited by a broadly protective vaccine.
Using this model, the present study examined (i) if
reactivation of murine lymphatic LTBI following the loss of
CD4+ T cells can be prevented by prior BCG vaccination, (ii) if
reactivation dynamics differ between vaccination routes, and (iii)
if the genetically modified BCG1BCG1419c strain can reduce
reactivation from lymphatic LTBI in this model.
MATERIALS AND METHODS
Mice
Female C57BL/6 mice were bred and maintained in the animal
facilities of the Australian Institute of Tropical Health and
Medicine at James Cook University, Australia. Mice were 6–8
weeks old at the time of vaccination, and maintained in a
biosafety level 3 facility under specific pathogen free conditions.
Bacteria
BCG Pasteur, BCG1BCG1419c and Mtb H37Rv were grown in
Middlebrook 7H9 broth (BD Biosciences) supplemented with
0.2% glycerol, 0.05% Tween 80, and 10% ADC enrichment (BD
Biosciences). Mid-logarithmic cultures were harvested, washed
in PBS and stored at−80◦C.
Vaccinations and Infections
C57BL/6 mice were immunized with 5 × 105 (i.t.) or 1 × 106
(s.c.) CFUs as described previously (25). For i.t. vaccination mice
were anesthetized via i.p. injections of Xylazine (5 mg/kg) and
Ketamine (50 mg/kg). Subsequently, the tongue was pulled out
sideways, the inoculum was administered into the oral cavity
and the nostrils were covered to direct the inoculum into the
trachea. 60 days after vaccination, mice were anesthetized via i.p.
injections of Xylazine (5 mg/kg) and Ketamine (50 mg/kg) and
were subsequently infected i.d. with 1 × 102 CFUMtb H37Rv in
the ear dermis in a volume of 50 µl.
Enumeration of Bacteria
At designated time points, lungs, spleen, and LNs were aseptically
removed. One third of the lung, half of the spleen and
two LNs were homogenized in sampling bags (Nasco Whirl-
Pak R©) containing 1ml of PBS supplemented with 0.05%
Tween 80. Serial dilutions of tissue homogenates were plated
onto Middlebrook 7H11 agar supplemented with 10% OADC
Enrichment (BD Biosciences) and ampicillin (25µg/ml) or
hygromycin (50µg/ml). CFU were determined after 3–4 weeks
incubation at 37◦C based on dilution factor and organ size.
Antibody-Mediated Depletion of CD4+
T Cells
CD4+ T cells were depleted from C57BL/6 mice by weekly
i.p. injections of 200 µg monoclonal antibody (mAb) against
CD4 (clone GK1.5, BioXCell, NH). The first injection was given
immediately afterMtb infection.
Cell Isolation
Intra-airway luminal cells were removed from the lung by
bronchial lavage. Spleen and lymph nodes were aseptically
removed. Lungs were perfused with PBS, mechanically disrupted
and digested for 30min with RPMI 1640 medium supplemented
with glutamine, Na-pyruvate, 2-ME, penicillin, streptomycin,
10% heat-inactivated FCS, collagenase D (Roche) and collagenase
type VIII (Sigma-Aldrich). Single cell suspensions were prepared
by passing organs through a 70µm cell strainer and red blood
cell lysis.
Flow Cytometry
Viable, red blood cell-depleted single splenocytes were stained
with mAb (all from BD Pharmingen) against CD4 (RM4-5),
CD8α (53-6.7), CD3 (500A2), CD44 (1M7) and NKp46 (29A1.4),
CD69 (H1.2F3), CD103 (M290), CD62L (MEL-14). After
washing the cells, samples were analyzed using a FortessaX20
analyzer (BD Biosciences, CA). Fixable Viability stain 780 (BD)
was used to exclude dead cells. Cell numbers were enumerated
by spiking single cell solutions with blank calibration particles
and calculated based on volume and organ size as described
previously (59).
Histology
The left lung lobes were collected aseptically, fixed overnight
with 4% w/v paraformaldehyde and embedded in paraffin. Two-
micrometers sections were stained with H&E and cell infiltration
was enumerated using ImageJ (60). The total surface area of the
left lung lobe was measured, followed by measuring all areas
of dense cell infiltration within the same lobe. Subsequently,
the proportion of cell infiltration relative to total surface area
was calculated.
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Multiplex Determination of Cytokines
Blood for serum analysis was collected in serum separator
tubes (BD), left for 30min at room temperature and spun at
12,000 g for 3min. Sera were stored at −20◦C until analysis.
Measurements were performed using a multiplex immunoassay
kit (MagPix). Heat maps for cytokine expression were prepared
with Microsoft Excel by plotting the fold increase of the mean
cytokine level relative to unvaccinated and untreated animals
(Figures 2D, 3D).
Data and Statistical Analysis
Flow cytometry data was analyzed using FlowJo software
(Treestar, CA). Statistical analysis was performed using
GraphPad Prism Version 7, GraphPad software, San Diego, CA
as indicated in individual figure legends. One-way analysis of
variance (ANOVA) followed by the Dunnett’s or Tukey’s multiple
comparison test was used. A P < 0.05 was considered significant.
RESULTS
Vaccination Profiling
To determine if BCG vaccination can prevent reactivation of
lymphatic murine LTBI following the loss of CD4+ cells, we
vaccinated C57BL/6 mice with two different strains of BCG:
BCG Pasteur (hereafter referred to as BCG) and a BCG Pasteur
strain deficient in the gene BCG1419c (hereafter referred to as
BCG1BCG1419c). BCG1BCG1419c vaccination reduced lung
pathology and Mtb replication in 3 mouse models (29, 35, 37),
two of which resemble chronic infection, and the other one
resembling reactivation from latent infection. Here, we further
evaluated BCG1BCG1419c’s potential as a vaccine candidate
against infection in a model resembling reactivation of LTBI
upon CD4 deprivation. Mice received the vaccines either as
a parenteral subcutaneous (s.c.) injection into the tail base
or directly into the lung via intratracheal (i.t.) vaccination
(Figure 1).
No weight loss or other adverse events were observed during
the vaccination period in all groups. 60 days after vaccination
we analyzed bacterial clearance, immune cell composition, lung
pathology, and serum cytokine profiles. In all vaccination settings
bacteria were efficiently cleared, and residual BCG colonies,
close to the detection limit, were detected in only 5 out of 40
mice (Figure 2A). As previously shown (25), i.t. vaccinations
significantly increased the numbers of various T cell subsets
in bronchioalveolar lavage fluid (BALF) and lung, including
CD44+ memory cells and CD69+CD103+ resident memory T
cells (Figure 2B). The largest increase in T cell numbers was
observed following i.t. BCG1BCG1419c vaccination, with a 1.5
to 2.3-fold increase in BALF and a 2.8 to 5.4-fold increase in lungs
in comparison to i.t. BCG (CD4+CD44+ 4.03-fold p = 0.0016;
CD4+CD69+CD103+ 5.41-fold p = 0.0012; CD8+CD44+ 2.8-
fold p = 0.0048; CD8+CD69+CD103+ 3.24-fold p = 0.0006).
Subcutaneous vaccinations induced a modest increase in T cell
numbers in spleen, BALF and lung (Supplementary Figure 1A),
and no differences in cellularity were detected in the inguinal
LN (Supplementary Figure 1A). We also assessed the level of
cell infiltration into the lung following the different vaccination
regimens by hematoxylin and eosin staining. Compared to naïve
mice, the level of cell infiltration after s.c. vaccination was not
increased (Figure 2C). Intratracheal vaccinations with both BCG
strains led to a low but significant influx of immune cells into the
lung which formed organized lymphoid structures, reminiscent
of inducible Bronchus Associated Lymphoid Tissue (iBALT)
(Figure 2C). Overall, low levels of circulating cytokines and
chemokines were detected in all groups, with very few significant
differences compared to unvaccinated animals (Figure 2D;
Supplementary Figure 1B). Although not reaching statistical
significance, relative to s.c. vaccination i.t. vaccination led
to reduced upregulation or even a downregulation of many
circulating cytokines, including IL-10, IL-6, IL-22, IL-1β, IL-18,
and IL-9 (Figure 2D). Collectively, these results demonstrate the
safety of all BCG vaccination regimens and indicate a superior
capacity of BCG1BCG1419c to induce memory T cells following
i.t. administration.
BCG Vaccination Prevents Systemic
Spread of Reactivated Lymphatic Mtb
Infection
We next assessed if BCG vaccination can prevent the progression
from LTBI to active murine TB as a consequence of CD4+
T cell depletion. C57BL/6 mice were infected with 100 cfu
Mtb H37Rv in the ear dermis 60 days after vaccination and
thereafter treated weekly with anti-CD4 mAb. Unvaccinated
anti-CD4 mAb-treated mice were used as a positive control for
reactivation of LTBI. Unvaccinatedmice that did not receive anti-
CD4 mAb served as a negative control in which Mtb remained
contained in the LN. We assessed the bacterial burden in ear-
draining LNs, spleen and lung at different time points (Figure 1).
As previously reported (51), unvaccinated untreated animals
almost exclusively containedMtb within the draining LNs of the
infected ear with very limited systemic spread. In some animals
few bacteria were detected in the spleen but almost never in
the lung (Figures 3A–C, black bars). In unvaccinated animals
treated with anti-CD4mAb,Mtb not only multiplied significantly
within the LNs over time but also exited the ear-draining LNs
and spread to spleen and lung in all animals (Figures 3A–C,
red bars). Prior vaccination with BCG or BCG1BCG1419c
significantly reduced replication of Mtb within the draining
lymph nodes and led to a significantly reduced spread of the
bacteria to the spleen (Figure 3B, gray and brown bars). Most
importantly, all vaccination strategies prevented spread of Mtb
to the lung following treatment with anti-CD4 mAb (Figure 3C,
gray and brown bars). Particularly at 120 days afterMtb infection,
unvaccinated animals that were treated with anti-CD4 contained
an average of 100,000 bacteria in the lung, whereas vaccinated
mice consistently showed CFU numbers below or near the
detection limit. No consistent patterns were observed, with both
BCG strains and vaccination routes being equally protective
(Supplementary Table 1). However, particularly during later
time points (d120), vaccinationwith BCG1BCG1419c led to very
low numbers of detectableMtb in spleen and lung, and also in the
LN after i.t. vaccination (Figures 3A–C, brown bars).
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FIGURE 1 | Schematic representation of infection model. Naïve C57BL/6 mice were vaccinated with BCG or BCG1BCG1419c via the s.c. or i.t. route. Sixty days
after vaccination a group of mice was sacrificed and assessed for clearance of the vaccine strain, cellular immune responses, lung histology, and serum
cytokines/chemokines. The remaining mice were infected i.d. with Mtb H37Rv in the ear dermis. At weekly intervals, mice received i.p. injections of a mAb against
mouse CD4 (GK1.5) or PBS. On days 14, 28, 50, and 120 p.i mice were sacrificed. Ear-draining LNs, spleen and lung were assessed for numbers of viable Mtb, T cell
populations by FACS, lung histology and serum cytokines. Unvaccinated mice without anti-CD4 treatment served as control for latent lymphatic TB and unvaccinated
mice treated with anti-CD4 were used as control for reactivation of latent lymphatic infection and systemic spread. BCG, Bacille Calmette–Guérin; Mtb,
Mycobacterium tuberculosis; TB, tuberculosis; s.c., subcutaneous; i.t., intratracheal; i.p., intraperitoneal; i.d., intradermal.
Consistent with low numbers of detectable bacteria
in the lung in BCG vaccinated groups, vaccination also
significantly reduced levels of pro-inflammatory cytokines,
such as MCP-3, IL-6, IL-18, Eotaxin, and RANTES relative
to unvaccinated, anti-CD4 mAb-treated controls (Figure 3D;
Supplementary Figure 2). While circulating serum levels
of IL-10 and IL-22 were reduced following i.t. vaccination
(Figure 2D; Supplementary Figure 1B), these cytokines
were upregulated in i.t. vaccinated animals following Mtb
infection compared to unvaccinated and s.c. vaccinated mice
(Figure 3B; Supplementary Figure 2). The levels of immune
cell infiltration into the lungs of s.c. vaccinated mice were
comparable to unvaccinated untreated mice (Figure 3E). In
contrast, unvaccinated mice that had received anti-CD4 mAb
showed significant and large-scale lung immunopathology
and cell infiltration (Figure 3E). Intratracheally vaccinated
animals maintained the level of immune cell infiltration that was
observed 60 days after vaccination around the bronchioli, despite
showing very low or even undetectable levels of CFU in the lung.
The overall infiltration scores of i.t. vaccinated mice were not
significantly different to unvaccinated anti-CD4-treated mice.
However, in contrast to the diffuse and widespread infiltration
seen in anti-CD4-treated unvaccinated animals, the infiltration
in i.t. vaccinated animals resembled well-organized and localized
iBALT clusters seen prior to Mtb infection (Figures 3E, 2C).
Together these data demonstrate that BCG vaccination prevents
reactivation of latent lymphatic murine TB regardless of the BCG
strain used for vaccination. The disparate cytokine levels and
immune cell infiltration patterns also suggest that prevention of
LTBI reactivation following s.c. and i.t. vaccination may depend
on different mechanisms.
Vaccine-Induced Prevention of
Reactivation Is Independent of CD4+
T Cells
Given that anti-CD4 treatment in unvaccinated mice
(Figures 3A–C, red bars) led to reactivation of LTBI, we
also investigated the efficiency of CD4+ T cell depletion. In
all groups, anti-CD4 mAb treatment led to almost complete
depletion of CD4+ T cells from ear-draining lymph nodes
as well as from the lung parenchyma (Figures 4A–D).
Depletion efficacy progressively increased from day 14
(Supplementary Figures 3A,B), and by day 120 after infection
only 7 out of 50 mice showed low residual levels of CD4+ T cells
in lymph nodes and lung (Figures 4C,D). In line with effective
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FIGURE 2 | Immune profiling prior to Mtb infection. Sixty days after vaccination with BCG or BCG1BCG1419c mice were assessed for: (A) Number of viable BCG in
inguinal LN, spleen and lung; (B) Number of total CD3+, CD3+CD4+, CD3+CD8+, CD3+CD4−CD8− (DN) and CD3−NKp46+ cells (left plots), as well as numbers
of total CD44+, CD44+CD69+CD103+ cells amongst CD3+CD4+ and CD3+CD8+ cells (right plots) in BALF and lung (C) lung immune cell infiltration; and
(D) serum cytokines/chemokines. Results are presented as individual data points (A,C), pooled data means ± SEM (B), representative images (C) and as a heat map
showing fold upregulation relative to naive controls (D) from two pooled independent experiments (n = 8–10) mice per group. Statistical analyses: One-way ANOVA
per cell type followed by Dunnett’s multiple comparisons test; significant differences relative to unvaccinated mice are indicated by asterisks: *p < 0.05; **p < 0.01;
***p < 0.001; ****p < 0.0001. Original magnification H&E × 25. BCG, Bacille Calmette–Guérin; s.c., subcutaneous; i.t., intratracheal; BALF, bronchioalveolar lavage
fluid; LN, lymph node.
depletion of CD4+ T cells, the frequency of CD8+ T cells
significantly increased in LN and lung of all anti-CD4-treated
mice (Figures 4E,F; Supplementary Figures 3C,D). However,
this proportional increase was initially not accompanied by
a numerical increase, because at days 14, 28 and 50 p.i. total
CD8+ T cell numbers in LN and lung were not statistically
significant between groups (Supplementary Figures 3E,F).
Only the anti CD4-treated unvaccinated group, the s.c.
BCG group and the s.c. BCG1BCG1419c group reached
statistical significance in the lung but not the LN at day 120 p.i.
(Figures 4G,H). Similarly, while CD44+ memory CD8+ T cells
proportionally increased following anti-CD4 mAb treatment
(Figures 4I,J; Supplementary Figures 3G,H), statistically
significant numerical increases were only observed at day 120
p.i. in the lung (Figures 4K,L; Supplementary Figures 3I,J).
These results suggest that depletion of CD4+ T cells does
not lead to a numerical replacement by CD8+ T cells to
control infection in the LN and lung. An additional statistical
comparison between unvaccinated anti-CD4-treated mice with
anti-CD4-treated vaccinated groups (red asterisks in Figure 4
and Supplementary Figure 3), revealed that the proportional
increase in CD8+ T cells in the lung of vaccinated mice was lower
in almost all vaccination groups at days 14, 28, and 50 after Mtb
infection (Supplementary Figure 3D). These differences were
not observed at 120 days after challenge and did not translate
into statistically significant numerical differences in total CD8+
T cell numbers (Supplementary Figure 3F) or memory CD8+
T cell numbers (Supplementary Figure 3J) for most vaccination
groups. Compared to unvaccinated anti-CD4-treated mice,
only i.t. BCG1BCG1419c vaccinated mice showed significantly
reduced numbers in total CD8+ (Figure 4H) and memory
CD8+ T cells numbers (Figure 4L) in the lung 120 days after
Mtb challenge. Furthermore, when we assessed memory CD8+
T cells for the expression of CD62L, CD69, and CD103 to
compare frequencies of effector-, central-, and resident memory
T cells, no obvious differences between the vaccination groups
and unvaccinated control groups were observed. However,
the increase in resident memory T cells that was only induced
by i.t. vaccination (Figure 2B) was maintained following Mtb
challenge in the lung (Supplementary Figure 4A). Overall these
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FIGURE 3 | BCG vaccination prevents reactivation of chronic lymphatic Mtb infection. Sixty days after vaccination with BCG or BCG1BCG1419c mice were infected
i.d. with 1 × 102 Mtb H37Rv. At weekly intervals, mice received an i.p. injection with a mAb against mouse CD4 (GK1.5) or PBS. On days 14, 28, 50, and 120 p.i
mice were sacrificed and the ear-draining LNs, spleen and lung were assessed for viable bacteria (A–C). Sera and lung sections from 120 days p.i. were also
assessed for cytokines/chemokines (D) and immune cell infiltration (E), respectively. Results are presented as pooled data means ± SEM (A–C), individual data points
and representative images (E) and as a heat map showing fold upregulation relative to unvaccinated untreated controls (D) from two pooled independent experiments
(n = 8–10 mice per group). Statistical analyses: One-way ANOVA per time point followed by Dunnett’s multiple comparisons test; significant differences relative to
unvaccinated anti CD4-treated mice are indicated by asterisks: *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001; dotted line in (A–C) represents CFU detection
limit. Original magnification H&E × 25. BCG, Bacille Calmette–Guérin; s.c., subcutaneous; i.t., intratracheal; LN, lymph node; mAb, monoclonal antibody.
data unambiguously demonstrate that BCG vaccination prevents
LTBI reactivation without a requirement for CD4+ T cells, and
suggest that numerical changes in CD8+ T cells are unlikely to
mediate the prevention of LTBI reactivation in this model.
DISCUSSION
Using a tractable mouse model, we provide compelling evidence
that immune control of reactivation of latent lymphatic Mtb
infection can be independent of vaccine-induced CD4+ T cells.
Treatment of latently infected mice with anti-CD4 mAb caused
LTBI reactivation and systemic spread of Mtb to spleen and
lung, mimicking the rapid progression from LTBI to TB in
HIV+ individuals (51). In contrast, prior vaccination with BCG
or BCG1BCG1419c prevented reactivation of Mtb from the
ear-draining lymph nodes and systemic spread, regardless of
the route of vaccine delivery. As most mice were depleted
of CD4+ T cells, our results unambiguously demonstrate that
vaccine-induced non-CD4+ T cell responses are sufficient to
control latent lymphaticMtb infection. Furthermore, we provide
evidence that the experimental TB vaccine BCG1BCG1419c
is safe and induces more memory T cells in BALF and lung
tissue following i.t. vaccination. Collectively, these results further
highlight the incomplete understanding about what constitutes
immunity in TB and why BCG only efficiently prevents some
forms of TB but not others (7, 8).
As expected, the frequency of CD8+ T cell in the infected
lymph nodes and lungs increased following the depletion of
CD4+ T cells. However, the total number of CD8+ T cells
only significantly increased in the lungs of unvaccinated anti-
CD4-treated mice and s.c. vaccinated mice at 120 days after
Mtb infection. Similarly, while the frequency of CD44+ memory
CD8+ T cells increased after depletion of CD4+ T cells, the
total numbers of these cells were only significantly increased at
120 days after Mtb infection in the lung of unvaccinated anti-
CD4-treated mice, s.c. vaccinated mice and i.t. BCG vaccinated
mice. Importantly, i.t. vaccination with BCG1BCG1419c did
not significantly increase CD8+ T cell populations, but even
significantly reduced CD8+ T cell populations relative to
unvaccinated anti-CD4-treated mice, despite providing robust
long-term protection against systemic spread of Mtb. These
results suggest that protection from reactivation is unlikely to be
exclusively mediated by an increase in CD8+ T cell populations,
but may perhaps rely on BCG1BCG1419c’s improved capacity
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FIGURE 4 | Vaccine-induced prevention of reactivation is independent of CD4+ T cells. (A,B) Representative FACS plots showing depletion of CD4+ T cells in LN
and Lung (gated on CD3+ cells) following administration of anti-CD4 mAb. (C,D) Frequencies of CD3+CD4+ cells in LN (C) and lung (D) at 120 days following Mtb
infection. (E,F) Frequencies of CD3+CD8+ cells in LN (E) and lung (F) at 120 days following Mtb infection. (G,H) Total numbers of CD3+CD8+ cells in LN and lung at
120 days following Mtb infection. (I,J) Frequencies of CD3+CD8+CD44+ cells in LN and lung at 120 days following Mtb infection. (K,J) Total number of
CD3+CD8+CD44+ cells in LN and lung at 120 days following Mtb infection. Results are presented as representative FACS plots (A,B) or individual data points
(C–L) from two pooled independent experiments (n = 8–10 mice per group). Statistical analyses: one-way ANOVA followed by Dunnett’s multiple comparisons test;
significant differences relative to unvaccinated mice are indicated by black asterisks; statistical differences relative to unvaccinated anti-CD4-treated mice are indicated
by red asterisks: *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. BCG, Bacille Calmette–Guérin; s.c., subcutaneous; i.t., intratracheal; LN, lymph node; mAb,
monoclonal antibody.
to stimulate local CD8+ IFNγ+ T lymphocytes in response to
Mtb antigens, as previously reported (29). This is consistent with
our previous study in which we had investigated if the boost
of memory CD8+ T cells, DN T cells, and NK cells with IL-
2/anti-IL-2 complexes can reverse the reactivation of lymphatic
LTBI. Although IL-2/anti-IL-2 complex treatment significantly
expanded these immune cell populations in LN, spleen and lung,
it did not prevent the systemic spread of Mtb after CD4+ T
cells were depleted (51). It was also recently shown that CD8+ T
cells fail to recognizeMtb-infectedmacrophages, due to bacterial-
induced decoymechanism, using distinct immunodominantMtb
antigens in an in vitro model (61). Further studies are needed to
investigate the role of antigen-specific CD8+ T cells and their
function in localized IFN-γ production in this model. On the
other hand, it could be that such protection from reactivation
of lymphatic LTBI could be mediated by activated macrophages,
which were shown to be more abundant in another model
of reactivation from latent-like infection upon corticosteroid
treatment, as opposed to IFNγ+ T cells (29). An increased
turnover rate of tissue macrophage was also suggested to be
important in TB reactivation in rhesus macaques (12). Further
studies will be required to formally confirm or to rule out
these hypotheses.
It was beyond the scope of this study to investigate which
immune mechanisms contain Mtb infection in the absence
of CD4+ T cells. Hence, we did not further investigate
humoral immunity, B cell characteristics or innate (trained)
immune responses. The importance of such immune responses
in TB has recently received renewed attention (62, 63). In
particular the distinct antibody glycosylation pattern identified
in human LTBI (64) has highlighted a potentially important
role for antibody-mediated effector function in controlling
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latent infection. Furthermore, there is increasing evidence that
Mtb exposure generates antibody isotypes in humans that can
inhibit mycobacterial infection (65), particularly in previously
uninfected individuals and individuals with LTBI (66). It is
also interesting to note that patients with active TB appear to
have dysfunctional circulating B cells, which regain function
following successful treatment (67). In support of our study,
it was also recently demonstrated that reactivation of LTBI in
a macaque model of TB/SIV co-infection was independent of
CD4+ T cells in at least one third of all animals (11). Collectively
these results point towards an important role of B cell-mediated
immunity in LTBI control as well as prevention ofMtb infection.
Our study extends these findings, and it is hence tempting
to speculate that BCG vaccination may prevent reactivation
of LTBI via B cell-mediated or trained innate immunity. The
tractable, reproducible and widely affordable mouse model
presented here, will allow to study the contributions of
these mechanisms on the dynamics of LTBI reactivation in
future studies.
The recombinant BCG1BCG1419c has previously been
shown to protect against Mtb challenge in chronic TB models
(29, 37). Our study also provides evidence that BCG1BCG1419c
induces equivalent protection in this model of LTBI reactivation
compared to conventional BCG against dissemination to
the lungs, and improved reduction of Mtb replication in
LN and spleens at the latest time point evaluated in this
work, 120 days post-infection (Figures 3A,C). Intratracheal
administration of BCG1BCG1419c induced significantly
higher numbers of memory T cells in the lung, including
cells with resident memory phenotype. Mucosal vaccination
with BCG1BCG1419c also induces significantly higher
levels of organized lymphoid structures in the lung, similar
to iBALT. Although these findings do not explain why
subcutaneous vaccination also prevents systemic spread of
Mtb in this model, there is increasing evidence that lymph
node architecture also changes significantly toward a B cell-
dominated structure following infection (68). Taken together,
it is possible that both s.c. and i.t. BCG vaccinations protect
against reactivation of LTBI by anatomically distinct but
functionally similar mechanisms that are geared towards
expansion of B cells. Further studies will have to investigate
these hypotheses.
Future investigations should also focus on determining
whether a LTBI model in genetically modified mouse strains
lacking particular immune cell subsets can be established. A
combination of different KOmouse strains and different vaccines
may ultimately reveal which cell type containsMtb in the absence
of CD4+ T cells. These studies should be accompanied by
detailed, high-dimensional imaging analyses of the immune cell
compositions in infected lymph nodes, spleen and lung to dissect
whether containment ofMtb largely occurs in the infected lymph
node or via preferential killing by vaccine-induced immune cell
subsets in the spleen and/or lung. The time-dependent spread
of Mtb from LN to spleen and lung following reactivation with
anti-CD4 suggests the presence of highly coordinated tissue-
specific immune responses that may involve macrophages and
other antigen presenting cells. Additionally, the absence of Mtb
CFU in the lung of vaccinated animals may also suggest that the
spread ofMtb from the lymphatics to the lung is interrupted, and
that vaccine-induced containment predominantly occurs in the
infected lymph nodes and the spleen. All of these hypotheses will
require further investigation.
In summary, our results provide compelling evidence
that BCG vaccination protects against reactivation of LTBI
independently of vaccine-induced CD4+ T cells. Our
findings suggest that protection from reactivation may
be independent of CD8+ T cell expansion and suggest a
potential role for B cells, antibody and/or trained immunity
in preventing reactivation. Finally, these results also underpin
the importance of our new small animal model of LTBI to gain
new insights into the correlates of BCG-induced immunity
againstMtb.
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